Frontline Apatinib/Gefitinib Combo Improves PFS in EGFR-Mutant NSCLC
September 20, 2020

Apatinib in combination with gefitinib in the first-line setting demonstrated superior progression-free survival (PFS) in patients with advanced EGFR-mutant non–small cell lung cancer.

Addition of Atezolizumab Improves pCR in Early TNBC, Irrespective of PD-L1 Status
September 20, 2020

Patients with triple-negative breast cancer experienced improved pathologic complete responses with the addition of neoadjuvant atezolizumab to chemotherapy.

Olaparib Significantly Improves OS in mCRPC Subgroup
September 20, 2020

The PARP inhibitor reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer, compared with enzalutamide or abiraterone plus prednisone.

Frontline Lorlatinib Improves PFS in Patients with Advanced ALK-Positive NSCLC
September 20, 2020

First-line treatment with the third-generation ALK TKI was also associated with higher overall and intracranial response rates in patients with ALK-positive non–small cell lung cancer.

Dostarlimab Shows Promising Antitumor Activity in Mismatch Repair Deficient, Proficient Endometrial Cancer
September 20, 2020

“Dostarlimab demonstrated durable antitumor activity in both dMMR and MMRp advanced and recurrent endometrial cancer,” said Ana Oaknin, MD, PhD.

ADC Continues to Show Clinical Activity in Heavily Pretreated Metastatic Urothelial Carcinoma
September 20, 2020

Sacituzumab govitecan-hziy induced significant activity with favorable tolerability in heavily pretreated patients with metastatic urothelial carcinoma.